<DOC>
	<DOCNO>NCT01054118</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( explores body drug ) , pharmacodynamics ( explores drug body ) single dose JNJ-38431055 , sitagliptin , co-administration JNJ-38431055 sitagliptin healthy overweight obese adult male volunteer .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Single Doses JNJ-38431055 , Sitagliptin , Co-administration JNJ-38431055 Sitagliptin</brief_title>
	<detailed_description>This double-blind ( neither physician volunteer know name assign study drug ) , placebo control ( substance contain medication ) , study healthy , overweight obese adult male volunteer . For volunteer , study consist screen phase ( 30 day ) , treatment phase volunteer receive 4 study treatment randomize ( study sequence assign chance ) sequence ( 28 day ) , follow-up phase ( 10 day ) . During treatment phase least 7 day 4 treatment . The four treatment JNJ-38431055 , sitagliptin , JNJ-38431055 sitagliptin , placebo . The following safety evaluation take throughout study : Electrocardiogram ( ECG painless procedure give picture electrical activity heart ) , blood pressure , heart rate , blood sample laboratory test . The primary outcome effect JNJ-38431055 sitagliptin glucagon like peptide-1 ( GLP-1 ) level . Study drug administer single oral dos separate least 7 day . The four treatment JNJ-38431055 , sitagliptin , JNJ-38431055 sitagliptin , placebo .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Body Mass Index ( BMI ) 27.0 38.0 kg/m2 ( inclusive ) Healthy basis physical examination include medical history , vital sign , 12lead ECG , screen lab test Men must agree use double barrier method birth control ( e.g. , condom use spermicide diaphragm , hormonal contraceptive intrauterine device female partner ) study three month follow last dose study medication , donate sperm study 3 month receive last dose study medication History , currently active , illness medical condition disorder Investigator consider clinically significant Smoker tobacco user within past 6 month History recent major surgery ( within 6 month study start ) Positive test alcohol and/or drug abuse Psychological and/or emotional problem , would render informed consent invalid , limit ability volunteer comply study requirement Any condition , opinion investigator , would compromise well volunteer study prevent volunteer meeting perform study requirement</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>